GOSSAMER BIO, INC. Stock-Based Compensation
GOSSAMER BIO, INC. (GOSS) reported Stock-Based Compensation of $8.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.46M, a 4.76% decline year-over-year.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.30M, a 162.12% increase year-over-year.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.90M, a 41.63% decline year-over-year.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.67M, a 44.94% decline year-over-year.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $10.55M, a 48.81% decline from fiscal 2024.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $20.62M, a 27.70% decline from fiscal 2023.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $28.52M, a 32.98% decline from fiscal 2022.
- GOSSAMER BIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $42.55M, a 32.94% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $8.77M 10-Q · filed 2026-08-13 | $11.66M derived: sum of 3 quarters · filed 2026-08-13 | $14.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $6.30M 10-Q · filed 2026-05-15 | $9.20M derived: sum of 2 quarters · filed 2026-05-15 | $11.87M derived: sum of 3 quarters · filed 2026-05-15 | $14.45M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $5.56M derived: sum of 2 quarters · filed 2026-03-17 | $8.15M derived: sum of 3 quarters · filed 2026-08-13 | $10.55M 10-K · filed 2026-03-17 |
| 2025-09-30 | $2.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.25M derived: sum of 2 quarters · filed 2026-08-13 | $7.66M 10-Q · filed 2025-11-05 | $12.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.99M 10-Q · filed 2026-08-13 | $9.96M derived: sum of 3 quarters · filed 2026-08-13 | $14.80M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.40M 10-Q · filed 2026-05-15 | $7.37M derived: sum of 2 quarters · filed 2026-05-15 | $12.21M derived: sum of 3 quarters · filed 2026-05-15 | $17.21M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $9.81M derived: sum of 2 quarters · filed 2026-03-17 | $14.81M derived: sum of 3 quarters · filed 2026-03-17 | $20.62M 10-K · filed 2026-03-17 |
| 2024-09-30 | $4.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $9.84M derived: sum of 2 quarters · filed 2025-11-05 | $15.65M 10-Q · filed 2025-11-05 | $21.69M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $5.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $10.81M 10-Q · filed 2025-08-05 | $16.84M derived: sum of 3 quarters · filed 2026-03-17 | $23.01M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $5.81M 10-Q · filed 2025-05-15 | $11.84M derived: sum of 2 quarters · filed 2026-03-17 | $18.00M derived: sum of 3 quarters · filed 2026-03-17 | $26.20M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $12.19M derived: sum of 2 quarters · filed 2026-03-17 | $20.39M derived: sum of 3 quarters · filed 2026-03-17 | $28.52M 10-K · filed 2026-03-17 |
| 2023-09-30 | $6.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $14.36M derived: sum of 2 quarters · filed 2024-11-07 | $22.49M 10-Q · filed 2024-11-07 | $33.94M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $8.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $16.32M 10-Q · filed 2024-08-12 | $27.77M derived: sum of 3 quarters · filed 2025-03-13 | $37.90M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $8.13M 10-Q · filed 2024-05-07 | $19.58M derived: sum of 2 quarters · filed 2025-03-13 | $29.70M derived: sum of 3 quarters · filed 2025-03-13 | $39.70M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $11.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $21.57M derived: sum of 2 quarters · filed 2025-03-13 | $31.57M derived: sum of 3 quarters · filed 2025-03-13 | $42.55M 10-K · filed 2025-03-13 |
| 2022-09-30 | $10.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $20.12M derived: sum of 2 quarters · filed 2023-11-09 | $31.10M 10-Q · filed 2023-11-09 | $38.76M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $10.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $20.98M 10-Q · filed 2023-08-08 | $28.64M derived: sum of 3 quarters · filed 2024-03-05 | $36.23M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $10.98M 10-Q · filed 2023-05-09 | $18.64M derived: sum of 2 quarters · filed 2024-03-05 | $26.23M derived: sum of 3 quarters · filed 2024-03-05 | $34.28M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $7.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $15.25M derived: sum of 2 quarters · filed 2024-03-05 | $23.30M derived: sum of 3 quarters · filed 2024-03-05 | $32.01M 10-K · filed 2024-03-05 |
| 2021-09-30 | $7.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $15.64M derived: sum of 2 quarters · filed 2022-11-03 | $24.35M 10-Q · filed 2022-11-03 | $37.03M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | $8.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $16.76M 10-Q · filed 2022-08-09 | $29.44M derived: sum of 3 quarters · filed 2023-03-17 | $38.37M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | $8.71M 10-Q · filed 2022-05-10 | $21.39M derived: sum of 2 quarters · filed 2023-03-17 | $30.31M derived: sum of 3 quarters · filed 2023-03-17 | $39.21M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $12.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $21.60M derived: sum of 2 quarters · filed 2023-03-17 | $30.50M derived: sum of 3 quarters · filed 2023-03-17 | $38.75M 10-K · filed 2023-03-17 |
| 2020-09-30 | $8.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $17.82M derived: sum of 2 quarters · filed 2021-11-08 | $26.07M 10-Q · filed 2021-11-08 | $32.93M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $17.14M 10-Q · filed 2021-08-09 | $24.01M derived: sum of 3 quarters · filed 2022-03-03 | $29.73M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $8.24M 10-Q · filed 2021-05-06 | $15.11M derived: sum of 2 quarters · filed 2022-03-03 | $20.83M derived: sum of 3 quarters · filed 2022-03-03 | $25.97M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $12.59M derived: sum of 2 quarters · filed 2022-03-03 | $17.73M derived: sum of 3 quarters · filed 2022-03-03 | $20.82M 10-K · filed 2022-03-03 |
| 2019-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $10.87M derived: sum of 2 quarters · filed 2020-11-10 | $13.96M 10-Q · filed 2020-11-10 | $24.76M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $5.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $8.23M 10-Q · filed 2020-08-11 | $19.03M derived: sum of 3 quarters · filed 2021-02-26 | $37.20M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $3.09M 10-Q · filed 2020-05-12 | $13.89M derived: sum of 2 quarters · filed 2021-02-26 | $32.06M derived: sum of 3 quarters · filed 2021-02-26 | $33.43M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $28.97M derived: sum of 2 quarters · filed 2021-02-26 | $30.34M derived: sum of 3 quarters · filed 2021-02-26 | $30.95M 10-K · filed 2021-02-26 |
| 2018-09-30 | $18.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $19.54M derived: sum of 2 quarters · filed 2019-11-12 | $20.15M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $1.98M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $605.00K 10-Q · filed 2019-05-14 | |||
| 2017-12-31 | $32.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |